Engineered immune cells take on HPV cancers in early trial

NCT ID NCT02379520

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new experimental treatment called HPVST cells in 32 people with HPV-related cancers that had returned or not responded to standard care. The cells are grown from the patient's own blood and trained to attack HPV-infected cancer cells. The goal was to find a safe dose and see if the cells can survive and fight the tumor. Some participants also received the drug nivolumab to boost the immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HPV-specific T cells (HPVSTs) with or without nivolumab
What this could lead to
If successful, this could point toward a new treatment option for patients with HPV-related cancers that have not responded to standard therapy.
What could go wrong
This is an early Phase 1 trial with only 32 participants, so results may not apply broadly. Side effects from the cell infusion or combination with nivolumab could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMAVIRUS POSITIVE ANAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.